Oncotelic Therapeutics, Inc.
OTLC
$0.03
$0.001.00%
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -40.99% | -20.33% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -40.99% | -20.41% | |||
| Operating Income | 54.48% | 20.41% | |||
| Income Before Tax | 115.23% | -100.62% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 115.23% | -100.89% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 3.52% | -17.27% | |||
| Net Income | 117.69% | -100.88% | |||
| EBIT | 54.48% | 20.41% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 118.37% | -100.86% | |||
| Normalized Basic EPS | 54.84% | 0.00% | |||
| EPS Diluted | 116.33% | -100.86% | |||
| Normalized Diluted EPS | 58.06% | 0.00% | |||
| Average Basic Shares Outstanding | 0.81% | 0.58% | |||
| Average Diluted Shares Outstanding | 5.43% | 0.58% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||